Personalizovaná farmakoterapie digoxinem
[Personalized pharmacotherapy of digoxin]
Jazyk čeština Země Česko Médium print
Typ dokumentu časopisecké články
PubMed
26075848
PII: 52310
- MeSH
- Bayesova věta MeSH
- digoxin farmakokinetika MeSH
- kardiotonika farmakokinetika MeSH
- lidé MeSH
- monitorování léčiv metody MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- srdeční selhání krev farmakoterapie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Názvy látek
- digoxin MeSH
- kardiotonika MeSH
INTRODUCTION: Therapeutic and toxic effects of digoxin are related to its serum concentrations, recent evidence suggests that a lower therapeutic range 0.5-0.9 ng/ml is associated with reduced mortality. AIM: To show the advantages of therapeutic drug monitoring for dosing of digoxin. METHOD: Trough serum levels of digoxin were estimated by immunoassay MEIA (AxSym Abbott). The long term serum concentration - time profile of digoxin has been predicted by the Bayesian analysis computer program MW-Pharm 3.30 MediWare. RESULTS: Sex case reports of the patients between 71 to 92 years are presented to show the different doses to receive digoxin levels in the therapeutic range. The doses varies between 0.03-0.25 mg per day. CONCLUSION: Therapeutic drug monitoring is very usefull for prediction of serum level of digoxin. There is no need to wait for a steady-state condition before performing therapeutic drug monitoring.
Cystatin C may be better than creatinine for digoxin dosing in older adults with atrial fibrillation